Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Equities

2315

CNE100005D27

Biotechnology & Medical Research

End-of-day quote Hong Kong S.E. 06:00:00 2024-05-09 pm EDT 5-day change 1st Jan Change
9.75 CNY -4.60% Intraday chart for Biocytogen Pharmaceuticals (Beijing) Co., Ltd. +9.55% -18.61%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies CI
Biocytogen Pharmaceuticals' Loss Narrows in 2023 MT
Biocytogen Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates CI
Biocytogen Pharmaceuticals Co., Ltd Announces Antibody Evaluation and Option Agreement with Gilead Sciences, Inc CI
Biocytogen Pharmaceuticals Co., Ltd. Announces Launch of New Sub-Brand, RenBiologics CI
Biocytogen Pharmaceuticals Gets License for Radiance Biopharma's Tumor Drug MT
Biocytogen Pharmaceuticals Co., Ltd. Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma CI
Biocytogen Pharmaceuticals Co., Ltd. and CtM Biotech Co., Ltd Achieve Milestone Progress in Co-Developing A TCR-Mimic Antibody-Based Multi-Specific T Cell Engager Targeting WT1/HLA-A02 CI
Biocytogen Strikes Multi-Target Antibody Deal With Neurocrine Biosciences MT
Biocytogen Pharmaceuticals Co., Ltd. Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences CI
Biocytogen, Ona Therapeutics Sign Agreement for Development of Antibody-Drug Conjugates MT
Biocytogen Pharmaceuticals Co., Ltd. Announce an Antibody Evaluation, Option and License Agreement with Ona Therapeutics CI
Biocytogen Pharmaceuticals Co., Ltd. Approves Election of Ms. Li Yan as A Non-Employee Representatives Supervisor of the Company CI
Biocytogen Pharmaceuticals Gets US Patent for RenMab Mice MT
Biocytogen Pharmaceuticals Adopts RenMice Name for Human Antibody Mice MT
Biocytogen Pharmaceuticals' RenMice Series-Fully Human Antibody and TCR Mouse Models-Showcase Biocytogen's Capabilities to Innovate the Discovery of Biologic Drugs CI
Myricx Enters into Antibody License Agreement with Biocytogen Pharmaceuticals Co., Ltd CI
Biocytogen Pharmaceuticals Co., Ltd. Establishes Two Business Divisions to Distinguish Preclinical Models and Services from Antibody Drug R&D CI
374,929,920 H Shares of Biocytogen Pharmaceuticals Co., Ltd. are subject to a Lock-Up Agreement Ending on 31-AUG-2023. CI
Biocytogen Pharmaceuticals' Loss Narrows in H1; Shares Up 12% MT
Biocytogen Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Biocytogen Pharmaceuticals Co., Ltd. Announces Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth CI
Biocytogen Pharmaceuticals Announces Grand Opening of Waltham, MA Facility CI
Biocytogen Pharmaceuticals' RenMab Platform Technology Gets Chinese Patent MT
Chart Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
More charts
Biocytogen Pharmaceuticals Beijing Co Ltd is a company mainly engaged in drug development business and preclinical research. The Company operates its business through five segments. The Gene-Editing services segment provides the customized gene-editing services based on animals as well as cells. The Pre-clinical Pharmacology and Efficacy Evaluation segment provides preclinical pharmacology services for the evaluation of drug efficacy and toxicity. The Animal Models Selling segment breeds and sells the animal models for the external and internal use. The Antibody Development segment utilises its antibody discovery platforms to identify antibodies which have the potential to become drug candidates. The Innovative Drugs Development segment is engaged in research and development of innovative drugs with a focus on oncology and autoimmune disease therapeutics. The Company also conducts its business through the Other segment.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
9.016 CNY
Average target price
14.21 CNY
Spread / Average Target
+57.66%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 2315 Stock
  4. News Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
  5. Biocytogen Pharmaceuticals Raises $60 Million in RemeGen-Backed Hong Kong IPO
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW